Novo Nordisk A/S (NVO)' Sales Assault on U.S. Diabetes Market Sets Rivalry
9/11/2013 7:46:58 AM
Drugmakers led by Novo Nordisk A/S (NOVOB) and Merck & Co. (MRK) are increasing sales efforts for their top-selling diabetes drugs to grab as much of the market as possible ahead of a wave of new therapies. At the start of this year, Novo, the world’s biggest maker of insulin, directed its sales force to boost promotion of the company’s drug Victoza. Soon after, revenue slowed for competing treatments from Merck and Bristol-Myers Squibb Co. (BMY), forcing those companies to put more resources behind their medicines and overhaul their strategies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by